BiotechTube
Comparative Biosciences

Comparative Biosciences

Sunnyvale, United States· Est.

Comparative Biosciences is a specialized preclinical CRO offering comprehensive services for drug development programs, with particular expertise in difficult and unique studies involving stem cells, devices, and combination therapies. Acquired by Genesis Biotechnology Group in 2020, it operates as part of the fully integrated GD3 platform, providing end-to-end support from discovery to clinical trials. The company serves a diverse client base ranging from small biotechs to large pharmaceutical companies, academia, and government agencies, leveraging its AAALAC-accredited, purpose-built facilities in Sunnyvale, California.

compbio.com

Private Company

Total funding raised: $1.7M

AI Company Overview

Comparative Biosciences is a specialized preclinical CRO offering comprehensive services for drug development programs, with particular expertise in difficult and unique studies involving stem cells, devices, and combination therapies. Acquired by Genesis Biotechnology Group in 2020, it operates as part of the fully integrated GD3 platform, providing end-to-end support from discovery to clinical trials. The company serves a diverse client base ranging from small biotechs to large pharmaceutical companies, academia, and government agencies, leveraging its AAALAC-accredited, purpose-built facilities in Sunnyvale, California.

OphthalmologyDermatologyOncologyFibrosisCardiovascularPulmonaryCNSMetabolic DiseaseInflammationImmunologyInfectious DiseaseOtologyMedical Devices

Technology Platform

Comparative Biosciences provides a comprehensive preclinical research services platform, including specialized surgical and disease modeling (ophthalmic, dermal, fibrosis, oncology), integrated GLP toxicology and histopathology, and advanced in vivo imaging and analytics to support client drug development programs.

Funding History

2
Total raised:$1.7M
Seed$1.2M
Grant$500K

Opportunities

Growth is driven by cross-selling within the integrated GD3 platform, increasing demand for complex preclinical models for novel modalities (cell/gene therapy, ADCs), and expansion through strategic acquisitions by the parent company.
The niche focus on difficult studies in ophthalmology and dermatology presents a high-barrier-to-entry opportunity.

Risk Factors

Key risks include dependence on biopharma R&D spending cycles, intense competition from larger CROs, operational risks associated with complex animal studies, and integration challenges within the growing GD3 network.
Retention of specialized scientific talent is also a critical challenge.

Competitive Landscape

Competes with large global preclinical CROs (Charles River, Labcorp) and niche specialty providers. Differentiation is achieved through deep expertise in complex ocular/dermal/surgical models, integration within the full-service GD3 platform, and a strong scientific, consultative approach led by PhD/DVM-level staff.

More companies in Digital Health & Biotech SaaS →More companies in United States →